Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds

Journal of Biochemical and Molecular Toxicology

Volumn 21, Issue 4, 2007, Pages 197-205

  Furlong, Clement E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Butyryl cholinesterase; Carboxylesterase; Chlorpyrifos; Chlorpyrifos oxon; Cytochromes P450; Diazinon; Diazoxon; Genetic variability; Paraoxon; Paraoxonase 1; Parathion; PON1

Indexed keywords

ARGININE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; CHLORPYRIFOS; CYTOCHROME P450; DIMPYLATE; INSECTICIDE; ISOENZYME; ORGANOPHOSPHORUS COMPOUND; PHOSPHOROTHIOIC ACID DERIVATIVE; PON1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; CATALYSIS; CONFERENCE PAPER; DETOXIFICATION; ENZYME ACTIVITY; ENZYME POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYDROLYSIS; LIVER METABOLISM; NONHUMAN; STOICHIOMETRY; STRUCTURE ACTIVITY RELATION; XENOBIOTIC METABOLISM; ANIMAL; BIOLOGICAL MODEL; BLOOD; DRUG DETOXIFICATION; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; LIVER MICROSOME; METABOLISM; MOUSE; MOUSE MUTANT; REVIEW; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; ARYLDIALKYLPHOSPHATASE; CATALYSIS; HUMANS; ISOENZYMES; METABOLIC DETOXICATION, DRUG; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES, LIVER; MODELS, BIOLOGICAL; ORGANOPHOSPHORUS COMPOUNDS; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; VARIATION (GENETICS);

EID: 36048956333     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20181     Document Type: Conference Paper

References (54)

1. Neal RA. Studies on the metabolism of diethyl-4-nitrophenyl phosphorothionate (parathion) in vitro. Biochem J 1971;103:183-191.
2. Sultatos LG, Shao M, Murphy SD. The role of hepatic biotransformation in mediating the acute toxicity of the phosphorothionate insecticide chlorpyrifos. Toxicol Appl Pharmacol 1984;73:60-68.
3. Sultatos LG, Costa LG, Murphy SD. Determination of organophosphorous insecticides, their oxygen analogs and metabolites by high pressure liquid chromatography. Chromatographia 1982;15:669-671.
4. Sultatos LG. Mammalian toxicology of organophosphorus pesticides. J Toxicol Environ Health 1994;43:271-289.
5. Dai D, Tang J, Rosem R, Hodgson E, Bienstockm RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825-831.
6. Tang J, Cao Y, Rose RL, Brimfield AA, Dai D, Goldstein JA, Hodgson E. Metabolism of chlorpyrifos by human cytochromes P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos 2001;29:1201-1204.
7. Burattia FM, Volpeb MT, Meneguzb A, Vittozzia L, Testai E. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol Appl Pharmacol 2003;186:143-154.
8. Usmani KA, Rose RL, Hodgson E. Effects of various chemicals on metabolism of testosterone by human liver microsomes and human cytochrome P450 3A4. Drug Metab Dispos 2003;31:384-391.
9. Usmani KA, Cho TM, Rose RL, Hodgson E. Inhibition of human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos 2006;34:1606-1614.
10. Hodgson E, Rose RL. Organophosphorus chemicals: Potent inhibitors of the human metabolism of steroid hormones and xenobiotics. Drug Metab Rev 2006;38:149-162.
11. Davies H, Richter RJ, Keifer M, Broomfield C, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334-336.
12. Li W-F, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Catalytic efficiency determines the in vivo efficacy of PON1 for detoxifying organophosphates. Pharmacogenetics 2000;10:767-780.
13. Costa LG, Vitalone A, Cole TB, Furlong CE. Modulation of paraoxonase (PON1) activity: Biochemical Pharmacology 2005;69(4):541-550.
14. Geldmacher-von Mallinkrodt M, Diepgen TL. The human serum paraoxonase - polymorphism and specificity. Toxicol Environ Chem 1988;18:179-196.
15. Diepgen TL, Geldmacher-von Mallinkrodt M. Interethnic differences in the detoxification of organophosphates: The human serum paraoxonase polymorphism. Arch Toxicol Suppl 1986;9:154-158.
16. Ortigoza-Ferado J, Richter R, Hornung SK, Motulsky AG, Furlong CE. Paraoxon hydrolysis in human serum mediated by a genetically variable arylesterase and albumin. Am J Hum Genet 1984;36:295-305.
17. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, Furlong CE. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: The mature protein retains its signal sequence. Biochemistry 1991;30:10141-10149.
18. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, La Du BN. Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 1999;19:2214-2225.
19. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-76.
20. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;53:598-608.
21. Eckerson HW, White CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-1138.
22. Li W-F, Costa LG, Furlong CE. Serum paraoxonase status: A major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993;40:337-346.
23. Jarvik GP, Jampsa R, Richter RJ, Carlson C, Rieder M, Nickerson D, Furlong CE. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. Pharmacogenetics 2003;13:291-295.
24. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: The quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos 2001;29:566-569.
25. Machin AF, Anderson PH, Quick MP, Waddel DF, Skibniewska KA, Howells LC. The metabolism of diaxinon in the liver and blood of species of varying susceptibility to diaxinon poisoning. Xenobiotica 1976;6:104.
26. Brealey CB, Walker CH, Baldwin BC. A-esterase activities in relation to the differential toxicity of pirimiphosmethyl to birds and mammals. Pestic Sci 1980;11:546-554.
27. Costa LG, Richter RJ, Murphy SD, Omeivn GS, Motulsky AG, Furlong CE. Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In: Costa LG, Galli CL, Murphy SD, editors. Toxicology of Pesticides: Experimental, Clinical and Regulatory Perspectives. Heidelberg: Springer-Verlag; 1987. pp. 262-266.
28. Main AR. The role of A-esterase in the acute toxicity of paraoxon, TEPP and parathion. Can J Biochem Physiol 1956;34:197-216.
29. Costa LG, McDonald BE, Murphy SD, Omeivn GS, Richter RJ, Motulsky AG, Furlong CE. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. Toxicol Appl Pharmacol 1990;103:66-76.
30. Aldridge WN. Serum esterases II. An enzyme hydrolysing diethyl-p-nitrophenyl acetate (E600) and its identity with the A-esterase of mammalian sera. Biochem J 1953;53:117-124.
31. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Pharmacogenet Genomics 2005;15:589-598.
32. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284-287.
33. Nolan RJ, Rick DL, Freshour NL, Saunders JH. Chlorpyrifos: Pharmacokinetics in human volunteers. Toxicol Appl Pharmacol 1984;73:8-15.
34. Yuknavage KL, Fenske RA, Kalman DA, Keifer MC, Furlong CE. Simulated dermal contamination with capillary samples and field cholinesterase biomonitoring. J Toxicol Environ Health 1997;51:35-45.
35. California Environmental Protection Agency, Air Resources Board. Report for the Application and Ambient Air Monitoring of Chlorpyrifos (and the Oxon Analogue) in Tulare County During Spring/Summer 1996. Sacramento, CA: California Air Resources Board; 1998. p. 28. Project Nos. C96-040 and C96-041. http://www.cdpr.ca.gov/docs/empm/pubs/tac/tacpdfs/chlrpfsa.pdf
36. Furlong C, Holland N, Richter R, Bradman A, Ho A, Eskenazi B. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. Pharmacogenet Genomics 2006;16:183-190.
37. Aldridge WN. Serum esterases I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate and a method for their determination. Biochem J 1953;53:110-117.
38. Hosokawa M, Endo T, Fujisawa M, Hara S, Iwata N, Sato Y, Satoh T Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 1995;23:1022-1027.
39. Satoh T, Suzuki S, Kawai N, Nakamura T, Hosokawa M. Toxicological significance in the cleavage of esterase-β-glucuronidase complex in liver microsomes by organophosphorus compounds. Chem Biol Interact 1999;119-120:471-478.
40. Fujikawa Y, Satoh T, Suganuma A, Suzuki S, Niikura Y, Yui S, Yamaura Y. Extremely sensitive biomarker of acute organophosphorus insecticide exposure. Hum Exp Toxicol 2005;24:333-336.
41. Medda S, Takeuchi K, Devore-Carter D, von Deimling O, Heymann E, Swank RT. An accessory protein identical to mouse egasyn is complexed with rat microsomal beta-glucuronidase and is identical to rat esterase-3. J Biol Chem 1987;262:7248-7253.
42. Tomino S, Paigen K. Egasyn, a protein complexed with microsomal beta-glucuronidase. J Biol Chem 1975;250:1146-1148.
43. Lusis AJ, Tomino S, Paigen K. Isolation, characterization, and radioimmunoassay of murine egasyn, a protein stabilizing glucuronidase membrane binding. J Biol Chem 1976;251:7753-7760.
44. Broomfield CA, Maxwell DM, Solana RP, Castro CA, Finger AV, Lenz DE. Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates. J Pharmacol Exp Ther 1991;259:633-638.
45. Manoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 2007;378:128-135.
46. Lockridge O, Schopfer LM, Winger G, Woods JH. Large scale purification of butyrylcholinesterase from human plasma suitable for injection into monkeys; a potential new therapeutic for protection against cocaine and nerve agent toxicity. J Med Chem Biol Radiol Def 2005;3:nihms5095.
47. Doctor BP, Saxena A. Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 2005;157-158:167-171.
48. Timchalk C, Nolan RJ, Mendrala AL, Dittenber DA, Brzak KA, Mattsson JL. A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol Sci 2002;66:34-53.
49. Huff R, Abou-Donia MB. In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase. Neurotoxicology 1995;16:281-290.
50. Cohen SD, Murphy SD. Comparative potentiation of malathion by triorthotolyl phosphate in four classes of vertebrates. Toxicol Appl Pharmacol 1970;16:701-708.
51. Choi J, Hodgson E, Rose RL. Inhibition of transpermethrin hydrolysis in human liver fractions by chloropyrifos oxon and carbaryl. Drug Metab Drug Interact 2004;20:233-246.
52. Wheelock CE, Eder KJ, Werner I, Huang H, Jones PD, Brammell BF, Elskus AA, Hammock BD. Individual variability in esterase activity and CYP1A levels in Chinook salmon (Oncorhynchus tshawytscha) exposed to esfenvalerate and chlorpyrifos. Aquat Toxicol 2005;74:172-192.
53. Yamada Y, Takatori T, Nagao M, Iwase H, Kuroda N, Yanagida J, Shinozuka T. Expression of paraoxonase isoform did not confer protection from acute sarin poisoning in the Tokyo subway terrorist attack. Int J Legal Med 2001;115:82-84.
54. 155 genotpye. Atheroscler Thromb Vasc Biol 2000;20:2442-2447.